文献速递临床免疫临床血液与体液

MAGLUMI免疫分析法检测血清抗GAD抗体在神经系统疾病中的钩状效应:当「错误」基质成为正确选择

Hook-effect in MAGLUMI immunoassay for serum anti-GAD antibodies in neurological disorders: When "wrong" matrix is the right choice.
PubMed 文献 · Clin Chim Acta · 2024-04-18

本病例报告描述一例疑似自身免疫性共济失调患者,血清抗GAD抗体在自动化学发光免疫分析中呈轻度异常(39.2 KIU/L),脑脊液浓度极高(>280 KIU/L)。血清稀释后呈非线性,1:1000稀释终点结果为276,500 KIU/L,提示钩状效应;脑脊液稀释呈线性,终点结果为4050 KIU/L。脑脊液抗GAD检测对确立临床诊断和识别血清钩状效应至关重要。

要点

  • 血清抗GAD轻度异常而脑脊液极高时,应警惕血清钩状效应。
  • 血清稀释呈非线性支持钩状效应,需稀释至线性范围获取真值。
  • 脑脊液抗GAD检测有助于确立抗GAD相关神经系统疾病诊断。

核心结论

  • 在抗GAD相关神经系统疾病中,血清抗GAD浓度可因钩状效应呈假性低值,脑脊液检测有助于确立诊断。

研究设计与样本

  • 病例报告:一例疑似自身免疫性共济失调患者,采用自动化学发光免疫分析法检测血清和脑脊液抗GAD抗体,并进行系列稀释。

主要发现

  • 血清抗GAD初测浓度为39.2 KIU/L,脑脊液浓度>280 KIU/L。
  • 血清不同稀释度结果呈非线性,1:1000稀释终点结果为276,500 KIU/L。
  • 脑脊液稀释呈线性,终点结果为4050 KIU/L。

关键数值与推荐

  • 血清抗GAD初测39.2 KIU/L,脑脊液>280 KIU/L;血清1:1000稀释终点276,500 KIU/L;脑脊液终点4050 KIU/L。

临床怎么用

  • 对疑似抗GAD相关神经系统疾病患者,若血清抗GAD轻度异常而临床高度怀疑,应进行血清稀释以排除钩状效应。
  • 脑脊液抗GAD检测可作为辅助手段,帮助识别血清钩状效应并支持诊断。

局限性

  • 本文为单例病例报告,结论需在更大样本中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibodies against glutamic acid decarboxylase (anti-GAD) are a valuable diagnostic tool to detect severe autoimmune conditions as type 1 diabetes mellitus (T1DM) and anti-GAD related neurological disorders, having the latter more often anti-GAD concentrations in serum multiple times higher than in the former. Automated immunoassays, either with ELISA or chemiluminescent technology, are validated for diagnostic use in serum with analytical ranges suitable for T1DM diagnosis. In a patient presenting with a suspected autoimmune ataxia, anti-GAD testing on an automated chemiluminescent immunoassay (CLIA) resulted in slightly abnormal concentrations in serum (39.2 KIU/L) and very high concentrations in CSF (>280 KIU/L), thus prompting to proceed to serum dilutions to exclude a false negative result and a misdiagnosis. Different dilutions of serum resulted in nonlinear concentrations with endpoint result of 276,500 KIU/L at dilution 1:1000. CSF dilution was instead linear with endpoint result of 4050 KIU/L. In this case report we found that anti-GAD testing in CSF was essential to establish the clinical diagnosis and to suspect hook-effect in serum due to the excess of autoantibodies in this severe autoimmune condition.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Musso G, Zoccarato M, Gallo N, et al. Hook-effect in MAGLUMI immunoassay for serum anti-GAD antibodies in neurological disorders: When "wrong" matrix is the right choice. Clin Chim Acta. 2024. PMID: 38642630. doi:10.1016/j.cca.2024.119679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。